Vesalius leads €8.3m series-B for Omeicos

Vesalius led the funding round via its Vesalius Biocapital II vehicle, alongside SMS Company Group and existing investors KfW Bank, IBB Beteiligungsgesellschaft through its vehicle VC Fonds Technologie Berlin, High-Tech Gründerfonds (HTGF), the Falck Revocable Trust, Ascenion and members of the company's management team.

Following the transaction, the company aims to start phase I clinical trials for its treatment of atrial fibrillation on 100 volunteers.

Previous funding
In April 2015, Vesalius led a €6.2m series-A round for the company alongside IBB, HTGF and KfW.

As part of the deal, life-sciences-focused asset management company Ascenion provided the business with a €550,000 subsidy from its Spinnovator grant programme, which is backed by the German Ministry of Education and Research.

Company
Headquartered in Berlin, Omeicos develops a molecule focusing on prevention and treatment of cardiovascular diseases. Founded in 2013, the pre-revenue business span out from the Max Delbrueck Center for Molecular Medicine.

People
Vesalius Biocapital – Christian Schneider (managing partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• DACH
• Venture
• Germany
• High-Tech Gründerfonds